Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).
EP. 1: IMpower010 Trial Evaluating Atezolizumab Versus Best Supportive Care (BSC)
Dr Millie Das, MD opens a discussion surrounding updates regarding non-small cell lung cancer (NSCLC) as presented at the 2022 World Conference on Lung Cancer (WCLC).
EP. 2: Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data
IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.
EP. 3: Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment
Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.
EP. 4: HUDSON Trial Overview and Key Takeaways
The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.
EP. 5: JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC
Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.
EP. 6: Emphasizing Biomarker-Driven Treatment and Individualized Care Strategies for Patients With NSCLC
2 Clarke Drive Cranbury, NJ 08512